We previously demonstrated the novel and promising potential of a therapeutic AAV2 expressing small interfering mTOR with universal cross-species specificity, including human, murine species, and monkey (AAV2-shmTOR),15 across various types of retinopathies using animal models such as choroidal neovascularization (CNV), oxygen-induced retinopathy (OIR), and diabetes-related retinopathy (DR) murine models.16 This evidence concerns the gene MTOR and retinal disorder.